Dual DNA-PK/AKT inhibition for the treatment of platinum-resistant cancer

Reference number 6843

Sectors: Pharmaceuticals

Industries: Pharmaceuticals

Novel compounds with dual DNA-PK/AKT inhibitor activity for the treatment of platinum-resistant cancers.

Proposed use

The dual inhibitors can be used to treat patients that indicate innate or acquired resistance to platinum-based drugs, such as cisplatin, or used as first line treatment in combination with platinum-based drugs to prevent the emergence of drug resistance and prolong survival of cancer patients.

Problem addressed

Platinum-based treatments, e.g. carboplatin and cisplatin, are commonly used to treat various cancers. Whilst initial response to these agents is high, emergence of platinum resistance is common. Ovarian, breast and lung cancers commonly progress as platinum-resistant cancers and display low survival rates. Recent evidence indicates that platinum-resistant cells can be present in primary tumours prior to chemotherapy treatment.

Platinum exposure induces AKT-dependent survival and DNA damage response in clinically platinum-resistant but not sensitive ovarian cancer cells. AKT relocates to the nucleus of cancer cells where it is phosphorylated at Serine473 by DNA-PK and this activation inhibits platinum-induced apoptosis, rendering platinum-based drugs ineffective. Inhibition of DNA-PK or AKT re-sensitises cisplatin-resistant ovarian cancer cells to platinum-based chemotherapy. Re-sensitisation is associated with prevention of AKT-mediated BAD phosphorylation.

Technology overview

Novel ATP-competitive inhibitors with dual inhibition of DNA-PK and AKT isoforms (pan-AKT) show efficacy in platinum-resistant ovarian cancer cells. Inhibition of DNA-PK/AKT restores platinum sensitivity in a panel of clinically resistant ovarian cancer cell lines. The use of dual DNA-PK/AKT inhibitors in platinum-resistant cancers or use in combination with platinum-based agents is a novel and effective approach to tackling cancers that have few treatment options post development of resistance.


  • The first known dual DNA-PK and AKT inhibitors
  • A treatment for drug resistant cancers that currently lack treatment options
  • Efficiently targets a common survival pathway in cancer
  • Potentially applicable to any cancer type that employs AKT- and DNA-PK-dependent survival response
  • Could potentially be used in combination with chemotherapeutic platinum-based agents to prevent the emergence of platinum-resistant tumours.
  • Tested in panel of platinum sensitive and resistant epithelial ovarian cancer cell lines.

Intellectual property information

Patent protecting the novel dual-DNA-PK/AKT inhibitory compounds and their use in platinum-resistant cancers and in combination with platinum-based chemotherapy or other chemotherapies, targeted agents and immune-oncology agents in cancer has been filed. The technology is available for exclusive licensing for further development, commercialization and/or collaborations with the inventor team.


Stronach, E. A., Cheraghchi-Bashi, A., Chen, M. & Gabra, H. Emerging Therapeutic Targets in Ovarian Cancer, 73-94 (Springer, 2011).

Cheraghchi-Bashi A, Parker CA, Curry E, Salazar JF, Gungor H, Saleem A, Cunnea P, et al. A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway. Oncotarget. 2015; 6:41736-41749.

Blagden SP, Hamilton AL, Mileshkin L, Wong S, Michael A, Hall M, Goh JC, Lisyanskaya AS, DeSilvio M, Frangou E, Stronach EA, Gopalakrishna P, Meniawy TM, Gabra H.. Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer. Clin Cancer Res. 2019 Mar 1;25(5):1472-1478.

Gungor H, Saleem A, Babar S, Dina R, El-Bahrawy MA, Curry E, Rama N, Chen M, Pickford E, Agarwal R, Blagden S, Carme S, Salinas C, Madison S, Krachey E, Santiago-Walker A, Smith DA, Morris SR, Stronach EA, Gabra H. Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies. J Nucl Med. 2015 Dec;56(12):1828-35.

Stronach EA, Chen M, Maginn EN, Agarwal R, Mills GB, Wasan H, Gabra H. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia. 2011 Nov;13(11):1069-80


Professor Hani Gabra

Emeritus Professor of Medical Oncology
Faculty of Medicine, Department of Surgery & Cancer

Visit personal site

Contact us about this technology


Dr Amritha Nair

Industry Partnerships and Commercialisation Senior Executive, Faculty of Medicine

Dr Amritha Nair is an Industry Partnerships and Commercialisation Senior Executive in the Faculty of Medicine at Imperial College London. Amritha works across the entire innovation lifecycle from assessment, protection, and management of Intellectual property; marketing of technologies primed for commercialisation and supporting commercialisation via licensing or spinouts. Amritha also supports researchers in their bids […]

Contact Amritha

[email protected]

Related technologies

A cytokine for wound healing and scar reduction

A cytokine for wound healing and scar reduction

A cytokine that promotes wound healing by accelerating re-epithelialization of the wound bed faster than FDA approved products. The treatment also has a potential to minimise scarring after injury. Find out more

A novel targeted drug delivery system

A novel targeted drug delivery system

A novel nanomedicine platform technology using biocompatible and biodegradable nanovesicles as carriers for a variety of clot-lysing thrombolytics Find out more

A novel targeted drug delivery system

A novel targeted drug delivery system

Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots. Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.